RT @QoLReC_OUH: Great work by Tolstrup and team💪 This RCT shows the importance of investigating the value of PRO before implementation in…
Thank you @QoLReC_OUH
Great work by Tolstrup and team💪 This RCT shows the importance of investigating the value of PRO before implementation into clinical practice! PRO is not a one-way traffic, still a lot to be done!! #EvidenceMatters #PRO #Melanoma #Cancer https://t.co
RT @Rbfriis: @TolstrupL published the results of an RCT evaluating the effect of #immunotherapy AE monitoring in #melanoma via #ePROs. Grea…
@TolstrupL published the results of an RCT evaluating the effect of #immunotherapy AE monitoring in #melanoma via #ePROs. Great work #CPSIG @PRO_ON_Dk @QoLReC_OUH @OUHhospital
https://t.co/xik4pdEHZN Clinical use of #ePROs results in more patient-initiated phone-contacts to the department indicating increased attention to AEs. However, the results do not justify the expansion of the pilot study. Well done, @TolstrupL
The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. https://t.co/WSEDknRdry
RT @KDieperink: @TolstrupL and colleagues did this great work 💪🏼 @SUND_SDU @OncoCareOUH
@TolstrupL and colleagues did this great work 💪🏼 @SUND_SDU @OncoCareOUH
New article: The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. https://t.co/OvYhVZuO43 #melanoma #oncology https://t.co/KooxHJQBgX
The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial https://t.co/a557N6e2Ql
The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial https://t.co/yfck3zYPH6